Antibiotic use in cystic fibrosis

Chronic pulmonary infections contribute significantly to the morbidity and mortality of patients with CF. The primary pathogens are Pseudomonas aeruginosa (PA) and Staphylococcus aureus. Hemophilus influenzae has been isolated from a significant number of patients also. A number of the beta-lactam and aminoglycoside antibiotics reportedly have altered pharmacokinetic variables in CF. Therapy of acute pulmonary deterioration consists of intravenous antibiotics for two weeks. Antibiotic selection is based on culture and sensitivity results. Currently, the combination of a broad-spectrum penicillin and an aminoglycoside seems to provide the best results. Prophylactic antibiotics are effective if the primary isolates are sensitive to the agents used. Chronic PA infections are problematic because effective oral agents are not available. Aerosolized antibiotics do not improve results over adequate systemic therapy for acute exacerbations. Questions regarding optimal dosages, frequency, and duration of therapy remain.

This article has been cited by other articles:

				H W. Kelly Pulmonary Clinical Pharmacy Practice Ann. Pharmacother., July 1, 2006; 40(7): 1407 - 1408. [Full Text] [PDF]

				S. E. H. West, L. Zeng, B. L. Lee, M. R. Kosorok, A. Laxova, M. J. Rock, M. J. Splaingard, and P. M. Farrell Respiratory Infections With Pseudomonas aeruginosa in Children With Cystic Fibrosis: Early Detection by Serology and Assessment of Risk Factors JAMA, June 12, 2002; 287(22): 2958 - 2967. [Abstract] [Full Text] [PDF]

				A. Whitehead, S.P. Conway, C. Etherington, N.A. Caldwell, N. Setchfield, and S. Bogle Once-daily tobramycin in the treatment of adult patients with cystic fibrosis Eur. Respir. J., February 1, 2002; 19(2): 303 - 309. [Abstract] [Full Text] [PDF]

				M. A. Bennett and R. D. Allen High-Technology Home Pharmacotherapy, I: An Overview of Antiinfective and Antineoplastic Therapies Journal of Pharmacy Practice, January 1, 1990; 3(1): 34 - 39. [Abstract] [PDF]